To ensure media and the physician community are continuously informed about the federal review process for COVID-19 vaccine candidates, the AMA will host a webinar series to gain fact-based insights from the nation's highest-ranking subject matter experts working to protect the health of the public.

With COVID-19 vaccine development moving at a rapid pace, the AMA webinar series is designed to provide transparency regarding the process for vaccine authorization or licensure, standards for review, and safety and efficacy data.

In the first episode of the webinar series, join AMA President Susan R. Bailey, M.D. as she discusses an overview of the FDA's vaccine review process with Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research at the FDA.

Dr. Bailey and Dr. Marks will also discuss what the process looks like for COVID-19 vaccine candidates and the differences between the Emergency Use Authorization (EUA) and Biologic License Application (BLA) pathways.

At a time when growing medical and public health disinformation is putting lives at risk, the webinar series is part of the AMA's ongoing work to restore trust in science and science-based decision-making among policymakers and the public. The AMA raises the voices of scientists, physicians, and other health professionals as we promote a national vision for health that is rooted in evidence and data and that is independent of political ideologies because lives depend on it.

What: AMA Webinar Series, Episode 1: FDA Review Process for COVID-19 Vaccine Candidates

When: Wednesday, October 7 at 2:00 p.m. Central Time

Who: Susan R. Bailey, M.D., AMA president, and Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research at the FDA

Registration: To watch the live webinar, register here

Contact: AMA media & editorial, media@ama-assn.org